KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Non-Current Assets (2016 - 2025)

Sarepta Therapeutics has reported Non-Current Assets over the past 15 years, most recently at $811.8 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $811.8 million for Q4 2025, down 8.76% from a year ago — trailing twelve months through Dec 2025 was $3.6 billion (up 10.11% YoY), and the annual figure for FY2025 was $811.8 million, down 8.76%.
  • Non-Current Assets for Q4 2025 was $811.8 million at Sarepta Therapeutics, up from $771.1 million in the prior quarter.
  • Over the last five years, Non-Current Assets for SRPT hit a ceiling of $1.0 billion in Q1 2025 and a floor of $476.9 million in Q3 2021.
  • Median Non-Current Assets over the past 5 years was $656.1 million (2023), compared with a mean of $683.7 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 38.81% in 2024 and later decreased 15.68% in 2025.
  • Sarepta Therapeutics' Non-Current Assets stood at $543.9 million in 2021, then increased by 4.9% to $570.5 million in 2022, then rose by 20.11% to $685.2 million in 2023, then grew by 29.84% to $889.7 million in 2024, then fell by 8.76% to $811.8 million in 2025.
  • The last three reported values for Non-Current Assets were $811.8 million (Q4 2025), $771.1 million (Q3 2025), and $1.0 billion (Q2 2025) per Business Quant data.